Avacta yet to receive update form MHRA on CE mark submission for Covid-19 test | 28 May 2021
28 May 2021 | 09:46am StockMarketWire.com - Cancer therapies and diagnostics Avacta said it had yet to receive any update from the UK Medicines and Healthcare products Regulatory Agency on the CE mark submission for its SARS-CoV-2 antigen lateral flow test. Its partner, Mologic Limited had filed the CE application. 'To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so,' the company said. At 9:46am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p Story provided by StockMarketWire.com Find out ...
Source: stockmarketwire.com